Corrigendum to “Rare primary non-neuroendocrine tumours of the sella”, [Diagn Histopathol 25(1), 8–15, January 2019]
Federico Roncaroli(Manchester Academic Health Science Centre), Kanna Gnanalingham, Mariam Mansoor(University of Manchester), Caterina Giannini(Mayo Clinic), Marco Faustini‐Fustini, Chiara Villa(Centre National de la Recherche Scientifique), Debajyoti Chatterjee(Post Graduate Institute of Medical Education and Research)
Cited by 2
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
|Endocrine Related Cancer|2017|357
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
|Journal of Clinical Oncology|2017|345